-
Published on Sep 21, 2016
Stephen
O'Hara, chief executive at OptiBiotix Health (LON:OPTI), talks to
Proactive Investors about the role the company will play in tackling
antibiotic resistance with its novel approach as all the member states
of the United Nations are set to sign a declaration agreeing to fight
the threat.
" We hope to start human studies by the start or second quarter of next year" he says, adding: "our solution will be a great benefit to hospitals and patients".
"This is a totally new concept in the market place because it has two actions: it kills bacteria and it stops them from re-attacking" O'Hara points out.
http://www.4-traders.com/OPTIBIOTIX-HEALTH-PLC-17109489/quotes/
www.optibiotix.com/
" We hope to start human studies by the start or second quarter of next year" he says, adding: "our solution will be a great benefit to hospitals and patients".
"This is a totally new concept in the market place because it has two actions: it kills bacteria and it stops them from re-attacking" O'Hara points out.
http://www.4-traders.com/OPTIBIOTIX-HEALTH-PLC-17109489/quotes/
www.optibiotix.com/
Optibiotix Health Plc (LON:#OPTI), The average loss was reported as 1.2 kilograms per week - https://t.co/xuIq4lDVK0 -— DirectorsTalk (@DirectorsTalk) September 6, 2016
We are delighted to have been nominated for the Best Technology at this years AIM Awards @AIM_Awards #AIMAwards2016— OptiBiotix Health (@OptiBiotix) September 14, 2016
No comments:
Post a Comment